Cagrilintide and retatrutide are two promising investigational weight-loss treatments, but they work differently. Explore amylin, GLP-1, CagriSema, and what clinical trials actually reveal.
Has retatrutide stopped working, or is your body adapting? Explore the science of weight-loss plateaus, metabolic adaptation, and what the latest clinical trials reveal about long-term weight-loss patterns.
Meet amycretin, also known as zenagamtide, Novo Nordisk’s investigational GLP-1 and amylin receptor agonist. Explore the latest clinical trial results, its potential for weight loss and diabetes, and how it differs from other emerging metabolic medications.
Retatrutide is making headlines with remarkable Phase 3 clinical trial results. From substantial weight loss to improvements in blood sugar and metabolic health, here’s what the latest research reveals—and what scientists still don’t know.
Noticing more hair in your brush after losing weight? Learn why significant weight loss can trigger hair shedding, what nutrients matter, and when regrowth may happen.
Losing weight is one thing. Building muscle afterward is another. Here’s why protein, strength training, and eating enough matter when your fitness goals change.
